Asgard featured on the Pharma Industry report about ATMPs in Sweden

Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader in ATMPs and for this it is important to manage research efforts in an efficient way, facilitating the clinical translation of such innovative therapies. Within this thematic, Pharma Industry Publishing AB published a report on the development of ATMPs in Sweden, where Asgard Therapeutics was featured.

http://dp.hpublication.com/publication/f4655caf/mobile/

Filipe Pereira, Cristiana Pires and Fábio Rosa, co-founders of Asgard Therapeutics, awarded with the Lund University and Sparbanken Skåne’s prize for future innovations

Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations. The award is intended to promote and encourage the utilization of knowledge at Lund University.

https://www.innovation.lu.se/article/framtidens-innovationer-prisade

Asgard Therapeutics awarded H2020 SMEi phase 1

Swedish start-up company Asgard Therapeutics has been awarded H2020 SMEi phase 1 in order to further develop a direct cell reprogramming technology for cancer immunotherapy.
Asgard Therapeutics was founded in 2018 as a spin-off from Lund University, targeting the urgent need for new cost-effective immunotherapies consistently effective in a broad range of patients. 
 
Through world-leading research at Lund University, the scientific founders of Asgard Therapeutics have developed a proprietary cell reprogramming technology. Based on this discovery, the team of Asgard Therapeutics is establishing a gene therapy – TrojanDC – that turns tumor cells into immune cells, triggering an antitumor immune response.
 “Currently available immunotherapies are only effective in a limited number of patients due to tumor heterogeneity, and often lose their efficacy as the tumor develops evasion mechanisms. In addition, immunotherapies come with high price. This new gene therapy approach will be transformative, providing patients with an ‘off-the-shelf’ solution that is at the same time highly personalized against their specific tumor”, says Cristiana Pires, co-founder and CEO of Asgard Therapeutics.
The SME Instrument supports new market-creating innovations, top class entrepreneurs and small companies with funding opportunities and acceleration services across Europe. Financial support from the SME Instrument, €50,000, will be used to further support TrojanDC development. Together with already obtained in-vivo proof- of-concept data, the SMEi P1 puts Asgard Therapeutics in an excellent position to rapidly progress the development of TrojanDC towards preclinical studies and later on clinical trials.
For more information:
Cristiana Pires
Co-founder and CEO of Asgard Therapeutics
+46(0)731 566 072 or cristiana.pires@asgardthx.com

Asgard Therapeutics was founded in 2018 as a spin-off from Lund University aiming to advance cancer immunotherapies by developing a paradigm-shifting gene therapy – TrojanDC. Driven by the urgent need for new cost-effective immunotherapies consistently effective in a broad range of patients, Asgard is developing the world’s first cancer immunotherapy based on direct cell reprogramming, forcing cancer cells to become immunogenic and unleashing the system against cancer.
https://cordis.europa.eu/project/id/882918